The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL ...

Roche and Genentech were unable to sufficiently demonstrate the benefit of using Columvi in an earlier treatment setting for ...

Genentech, part of the Roche Group ( OTCQX:RHHBY) ( OTCQX:RHHBF) ( OTCPK:RHHVF ), announced that the U.S. FDA has rejected ...

F. Hoffmann-La Roche Ltd. Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas 1,2. New data ...

Roche’s stock has lost 4.6% in the year so far compared with the industry’s decline of 1.6%.. Image Source: Zacks Investment Research Roche is evaluating Columvi in combination with other ...

Columvi is an intravenously administered bispecific T-cell engager (BiTE), targeting CD3 on T-cells and redirecting them to CD20-expressing cancer B cells, resulting in potent and selective T cell ...

Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response rate and a median duration of response of 1.5 years 1 Given over a fixed period of time, Columvi ...

(RTTNews) - Swiss drug major Roche Holding AG (RHHBY) announced Tuesday that the European Commission has granted conditional marketing authorisation for Columvi (glofitamab) to treat people with ...